These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 1609547)

  • 1. Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain.
    Tacket CO; Hone DM; Losonsky GA; Guers L; Edelman R; Levine MM
    Vaccine; 1992; 10(7):443-6. PubMed ID: 1609547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers.
    Tacket CO; Hone DM; Curtiss R; Kelly SM; Losonsky G; Guers L; Harris AM; Edelman R; Levine MM
    Infect Immun; 1992 Feb; 60(2):536-41. PubMed ID: 1730487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system.
    Tacket CO; Kelly SM; Schödel F; Losonsky G; Nataro JP; Edelman R; Levine MM; Curtiss R
    Infect Immun; 1997 Aug; 65(8):3381-5. PubMed ID: 9234801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans.
    Tacket CO; Sztein MB; Losonsky GA; Wasserman SS; Nataro JP; Edelman R; Pickard D; Dougan G; Chatfield SN; Levine MM
    Infect Immun; 1997 Feb; 65(2):452-6. PubMed ID: 9009296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant induction of CD4+ and CD8+ T cell responses in volunteers immunized with Salmonella enterica serovar typhi strain CVD 908-htrA.
    Salerno-Gonçalves R; Wyant TL; Pasetti MF; Fernandez-Viña M; Tacket CO; Levine MM; Sztein MB
    J Immunol; 2003 Mar; 170(5):2734-41. PubMed ID: 12594304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine.
    Hone DM; Tacket CO; Harris AM; Kay B; Losonsky G; Levine MM
    J Clin Invest; 1992 Aug; 90(2):412-20. PubMed ID: 1644914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations.
    Kirkpatrick BD; Tenney KM; Larsson CJ; O'Neill JP; Ventrone C; Bentley M; Upton A; Hindle Z; Fidler C; Kutzko D; Holdridge R; Lapointe C; Hamlet S; Chatfield SN
    J Infect Dis; 2005 Aug; 192(3):360-6. PubMed ID: 15995948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers.
    DiPetrillo MD; Tibbetts T; Kleanthous H; Killeen KP; Hohmann EL
    Vaccine; 1999 Oct; 18(5-6):449-59. PubMed ID: 10519934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers.
    Hohmann EL; Oletta CA; Killeen KP; Miller SI
    J Infect Dis; 1996 Jun; 173(6):1408-14. PubMed ID: 8648213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers.
    Hohmann EL; Oletta CA; Miller SI
    Vaccine; 1996 Jan; 14(1):19-24. PubMed ID: 8821644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers.
    Tacket CO; Sztein MB; Wasserman SS; Losonsky G; Kotloff KL; Wyant TL; Nataro JP; Edelman R; Perry J; Bedford P; Brown D; Chatfield S; Dougan G; Levine MM
    Infect Immun; 2000 Mar; 68(3):1196-201. PubMed ID: 10678926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers.
    Metzger WG; Mansouri E; Kronawitter M; Diescher S; Soerensen M; Hurwitz R; Bumann D; Aebischer T; Von Specht BU; Meyer TF
    Vaccine; 2004 Jun; 22(17-18):2273-7. PubMed ID: 15149786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated DeltaguaBA Salmonella enterica serovar Typhi strain CVD 915.
    Wang JY; Pasetti MF; Noriega FR; Anderson RJ; Wasserman SS; Galen JE; Sztein MB; Levine MM
    Infect Immun; 2001 Aug; 69(8):4734-41. PubMed ID: 11447145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica serovar Typhi strains as live mucosal vaccines and as live vectors.
    Pickett TE; Pasetti MF; Galen JE; Sztein MB; Levine MM
    Infect Immun; 2000 Jan; 68(1):205-13. PubMed ID: 10603389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA.
    Frey SE; Lottenbach KR; Hill H; Blevins TP; Yu Y; Zhang Y; Brenneman KE; Kelly-Aehle SM; McDonald C; Jansen A; Curtiss R
    Vaccine; 2013 Oct; 31(42):4874-80. PubMed ID: 23916987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuated Salmonella as live oral vaccines against typhoid fever and as live vectors.
    Levine MM; Galen J; Barry E; Noriega F; Chatfield S; Sztein M; Dougan G; Tacket C
    J Biotechnol; 1996 Jan; 44(1-3):193-6. PubMed ID: 8717403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of an attenuated Salmonella enterica serovar Paratyphi A vaccine candidate.
    Xiong K; Chen Z; Zhu C; Li J; Hu X; Rao X; Cong Y
    Int J Med Microbiol; 2015 Sep; 305(6):563-71. PubMed ID: 26239100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression.
    Tacket CO; Levine MM
    Clin Infect Dis; 2007 Jul; 45 Suppl 1():S20-3. PubMed ID: 17582563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a.
    Tacket CO; Forrest B; Morona R; Attridge SR; LaBrooy J; Tall BD; Reymann M; Rowley D; Levine MM
    Infect Immun; 1990 Jun; 58(6):1620-7. PubMed ID: 1692807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity.
    Dilts DA; Riesenfeld-Orn I; Fulginiti JP; Ekwall E; Granert C; Nonenmacher J; Brey RN; Cryz SJ; Karlsson K; Bergman K; Thompson T; Hu B; Brückner AH; Lindberg AA
    Vaccine; 2000 Feb; 18(15):1473-84. PubMed ID: 10618545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.